# NRG-GY017 (NCT03738228)

> Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03738228
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB2 Cervical Cancer AJCC v8; Stage II Cervical Cancer AJCC v8; Stage IIA Cervical Cancer AJCC v8; Stage IIA1 Cervical Cancer AJCC v8; Stage IIA2 Cervical Cancer AJCC v8; Stage IIB Cervical Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8
- Interventions: Atezolizumab; Brachytherapy; Cisplatin; Radiation Therapy
- Enrollment: 40
- Primary outcome: Immune Response

## Indexed commentary on NRG-GY017 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 2
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nrg-gy017-nct03738228